Peptides on the Docket
What the FDA's compounding committee panel's outcome means for the industry
Hosted by Elias Arjan · featuring Gayland Hethcoat
The Healthspan Collective has been featured in
A clear-eyed unpacking of the FDA advisory committee's peptide review — what was recommended, what remains undecided, and what it means for the industry.
What the committee recommended
A peptide-by-peptide read-out of the two-day session — where BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon landed with the panel.
What it does — and doesn't — decide
The 503A Bulks List, the FDA's discretion, and why the committee's advice isn't the final word.
What it means for the industry
Practical implications for compounding pharmacies, clinicians, and companies working with these peptides.
How to prepare
Risk considerations and sensible next steps while the regulatory picture develops.
Founder & Chief Community Officer
Healthspan CollectiveA leading healthspan advocate, educator, and speaker, and co-founder of PRUVN Research — known for a relentless commitment to evidence-based wellness and cutting-edge longevity science.
Gayland Hethcoat
Counsel
ArentFox SchiffA strategic legal partner to providers and innovators across health care — hospitals, physician practices, telehealth, digital therapeutics, and AI-enabled health technology — advising where regulated care meets consumer wellness, data privacy, and advertising law. Leads ArentFox Schiff's Longevity & Healthspan Industry Group.
Klaudia Balogh
Director of Communication
Healthspan CollectiveOur first live session — more announced soon.
- Jul 25Hero WebinarProviders + Consumers11:00–11:45 AM PDT · 30 min + 15 min Q&A
Peptides on the Docket
FDA policy · Peptides · Compounding
Inside the Committee's Recommendations
A peptide-by-peptide look at where BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon landed after the two-day review — and the reasoning behind the panel's votes.
Advice, Not a Verdict
The committee recommends; the FDA decides. What the 503A Bulks List process actually is, and the paths the agency could take from here.
What It Means for the Industry
Practical implications for compounding pharmacies, clinicians, and companies building with these substances — and how to position for what comes next.
And much more
Everything you need to know before you register.
Still have a question?
We're happy to help before you register.
Free to attend — replay included. Reserve your seat before it fills up.